Jian Liu
College of Medicine
Zhejiang University
China
Biography
She has finished the science project “Pharmacogenetic of CYP3A and MDR-1 in relation to population pharmacokinetics of docetaxel in Chinese patients” as PI. And, as the main participants, She has also finished the projects “Twelfth Five-Year significant new drugs creation plan sponsored by Ministry of science and technology”, “Pharmacogenetics of sirolimus and its clinical safety”, “The genetic polymorphism in relation to population pharmacokinetics of tacrolimus in Chinese patients” and “Effect of CYP450 polymorphism on the pharmacokinetics of agomelatine risperidone in Chinese healthy male volunteers”, “The reserch on the molecular mechanism of imatinib resistance of non small cell lung cancer mediated by tyrosine phosphatase Shp2 regulates epithelial mesenchymal”. As Sub-PI, She has completed more than 20 bioequivalence, pharmacokinetics, and phase I clinical trials. Now, as PI, She is undertaking a bioequivalence study.
Research Interest
His main research interests include Clinical Pharmacology, pharmacokinetics
